drugset / Trial / NCT01755975
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Phase 1/2
Completed
49 enrolled
Memorial Sloan Kettering Cancer Center
Biologics, Inc. · collabCelgene Corporation · collabSt. Francis Hospital & Medical Center, Hartford CT · collabUniversity of Nebraska · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.
Timeline
- Start
- 2012-12
- Primary completion
- 2023-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Romidepsin | Peptide | — | Intravenous |